|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 31/7076 | (2006.01) |
| A61K 38/21 | (2006.01) | ||
| A61P 25/00 | (2006.01) | ||
| A61P 25/28 | (2006.01) |
| (11) | Number of the document | 3332789 |
| (13) | Kind of document | T |
| (96) | European patent application number | 18151634.5 |
| Date of filing the European patent application | 2005-12-20 | |
| (97) | Date of publication of the European application | 2018-06-13 |
| (45) | Date of publication and mention of the grant of the patent | 2022-04-06 |
| (46) | Date of publication of the claims translation | 2022-07-25 |
| (30) | Number | Date | Country code |
| 638669 P | 2004-12-22 | US | |
| 04106909 | 2004-12-22 | EP |
| (72) |
De Luca, Giampiero , CH
Ythier, Amaud , CH
Munafo, Alain , CH
Lopez-Bresnahan, Maria , US
|
| (73) |
Merck Serono SA ,
Centre Industriel, 1267 Coinsins, Vaud,
CH
|
| (74) |
Aušra PAKĖNIENĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Kladribino režimas, skirtas išsėtinės sklerozės gydymui |
| CLADRIBINE REGIMEN FOR TREATING MULTIPLE SCLEROSIS |
| Payment date | Validity (years) | Amount | |
| 2024-11-22 | 20 | 347.00 EUR |